Advertisement

Topics

Allergan Takes to the Clinic the First Alzheimer’s Drug from a €3Bn Deal

08:32 EDT 1 Sep 2017 | Labiotech.eu

Allergan’s partner Heptares Therapeutics has dosed the first patient with a GPCR drug to treat major symptoms of Alzheimer’s disease. A year ago, Allergan signed a massive deal of up to €3Bn with Heptares Therapeutics for the development of drugs ...

This awesome article Allergan Takes to the Clinic the First Alzheimer’s Drug from a €3Bn Deal appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: Allergan Takes to the Clinic the First Alzheimer’s Drug from a €3Bn Deal

NEXT ARTICLE

More From BioPortfolio on "Allergan Takes to the Clinic the First Alzheimer’s Drug from a €3Bn Deal"

Quick Search
Advertisement
 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...